TOP 20 Archives - Page 2 of 12

TOP 20

Top 20 Biopharma Deal Terminations of 2024

Shots: In the Biopharma industry, navigating M&A and licensing deals is challenging due to strict antitrust laws and shifting regulations. When these pressures create significant risks, nullifying or restructuring existing agreements can be the most rational and strategic response In 2024, the termination of the $4.45B deal between Adaptimmune and Genentech became a major talking…

May 14, 2025

Top 20 Biopharma Companies of 2025

Shots: Driven by innovation and a steadfast commitment to advancing cutting-edge therapies, the biopharma industry experienced robust growth in 2024, marked by significant revenue milestones With a projected compound annual growth rate (CAGR) of 12.87%, the global biopharma market is expected to reach $1.41 trillion by 2032. In 2024, Pfizer led the industry with total…

April 24, 2025

Top 20 Radiopharmaceutical Companies of 2025

Shots:Imaging, precision diagnostics, and targeted therapies are among the many ways radiopharmaceuticals improve patient outcomes and meet unmet healthcare needsIn 2024, the global radiopharmaceuticals market was valued at $6.74B and is envisioned to grow to $13.67B by 2033, exhibiting a CAGR of 8.2% from 2024 to 2033. Lilly ranks first in our list…

March 27, 2025

20 Women Health Tech Companies of 2025

Shots: Technology is revolutionizing women’s healthcare, empowering them with tools to better understand and manage their health. The health tech industry offers a broad spectrum of preventative, diagnostic, therapeutic, and support services tailored for women In celebration of Women's Day, PharmaShots honors the healthcare industry’s dedication to innovation and its unwavering commitment to improving women’s…

March 17, 2025

Top 20 Healthcare IPOs of 2024

Shots:Initial Public Offerings (IPOs) serve as a strategic avenue for private healthcare companies to enhance liquidity, secure capital, and strengthen market presence. Beyond fundraising, going public often paves the way for strategic partnerships and expanded industry influence.Galderma led the IPO landscape in 2024, raising a staggering $2.54B, followed by BrightSpring Health Services and…

February 27, 2025

Top 20 Life Sciences Deals of 2024 by Total Deal Value 

Top 20 Life Sciences Deals of 2024 by Total Deal Value Shots: Life Sciences Dealmaking 2024 outlined a new genre of strategies for shaping global healthcare landscapes by targeting emerging technologies and addressing unmet needsIn 2024, Arrowhead’s global licensing and commercialization deal with Sarepta Therapeutics for $11.37B ranked first in the list, followed by…

February 20, 2025

20 Emerging Animal Health Companies of India

20 Emerging Animal Health Companies of IndiaShots:Owing to the agrarian origin and rise in pet ownership trends, the animal healthcare sector in India has witnessed a significant boomIn 2023, the animal healthcare market size was valued at $1.9B and is anticipated to grow to $4.3B by 2030, registering a CAGR of 12.3%…

February 10, 2025

Top 20 Biopharma M&A of 2024 by Total Deal Value

Top 20 Biopharma M&A of 2024 by Total Deal ValueShots:Dealmaking in 2024 experienced fluctuations due to regulatory challenges and increasing pressure from the Inflation Reduction ActThe highest-value deal of the year was Vertex’s acquisition of Alpine Immune Sciences for $4.9B, followed by Gilead’s acquisition of CymaBay for $4.3B and Lilly’s acquisition of…

February 6, 2025

Top 20 Animal Health Companies of 2024

Shots:The WHO’s One Health policy is driving innovation in animal health, emphasizing the intersection of human, animal, and environmental careThe global animal health market, valued at $62.4B in 2023, is expected to grow at a CAGR of 9%, reaching $114B by 2030PharmaShots presents a comprehensive report on the Top 20 Animal Health Companies of…

December 12, 2024

Top 20 Cell and Gene Therapy Companies of 2024

Shots:Cell and gene therapies provide a promising opportunity to enhance care for unmet healthcare needs. Biopharma companies are actively exploring these therapies across multiple indications to address healthcare gaps in rare and chronic diseasesIn 2023, the cell and gene therapy market was valued at $18.2B and is projected to grow to $117.46B by…

November 28, 2024